SARS-CoV-2 infection has a severe course in a small percentage of children. Remdesivir has shown promising results in reducing hospitalisation time in adults, but data on mortality rate are conflicting and few studies are available on its use use in antivirals in children. We performed a quick narrative review of the available literature data regarding the usage of remdesivir in children and neonates. In children, remdesivir showed good safety profile, however bradicardia events have been reported in children. Remdesivir is cur-rently recommended by several guidelines in some subgroups of children with severe COVID-19, and should also be considered in critically ill patients, always in the context of the overall clinical picture and drug avail-ability. (www.actabiomedica.it).

Use of remdesivir in children with covid-19 infection: A quick narrative review / La Tessa A.; Motisi M.A.; Marseglia G.L.; Cardinale F.; Licari A.; Manti S.; Tosca M.; Del Giudice M.M.; De Filippo M.; Galli L.; Chiappini E.. - In: ACTA BIO-MEDICA DE L'ATENEO PARMENSE. - ISSN 0392-4203. - ELETTRONICO. - 92:(2021), pp. e2021524-e2021529. [10.23750/ABM.V92IS7.12396]

Use of remdesivir in children with covid-19 infection: A quick narrative review

La Tessa A.;Motisi M. A.;Galli L.;Chiappini E.
2021

Abstract

SARS-CoV-2 infection has a severe course in a small percentage of children. Remdesivir has shown promising results in reducing hospitalisation time in adults, but data on mortality rate are conflicting and few studies are available on its use use in antivirals in children. We performed a quick narrative review of the available literature data regarding the usage of remdesivir in children and neonates. In children, remdesivir showed good safety profile, however bradicardia events have been reported in children. Remdesivir is cur-rently recommended by several guidelines in some subgroups of children with severe COVID-19, and should also be considered in critically ill patients, always in the context of the overall clinical picture and drug avail-ability. (www.actabiomedica.it).
2021
92
e2021524
e2021529
La Tessa A.; Motisi M.A.; Marseglia G.L.; Cardinale F.; Licari A.; Manti S.; Tosca M.; Del Giudice M.M.; De Filippo M.; Galli L.; Chiappini E.
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/1256324
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 10
  • ???jsp.display-item.citation.isi??? ND
social impact